Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators Kanter JE; Bornfeldt KETrends Endocrinol Metab 2013[Mar]; 24 (3): 137-44Monocytes and macrophages respond to and govern inflammation by producing a plethora of inflammatory modulators, including cytokines, chemokines, and arachidonic acid (C20:4)-derived lipid mediators. One of the most prevalent inflammatory diseases is cardiovascular disease, caused by atherosclerosis, and accelerated by diabetes. Recent research has demonstrated that monocytes/macrophages from diabetic mice and humans with type 1 diabetes show upregulation of the enzyme, acyl-CoA synthetase 1 (ACSL1), which promotes C20:4 metabolism, and that ACSL1 inhibition selectively protects these cells from the inflammatory and proatherosclerotic effects of diabetes, in mice. Increased understanding of the role of ACSL1 and other culprits in monocytes/macrophages in inflammation and diabetes-accelerated atherosclerosis offers hope for new treatment strategies to combat diabetic vascular disease.|Animals[MESH]|Arachidonic Acid/metabolism[MESH]|Atherosclerosis/*etiology[MESH]|Cardiovascular Diseases/etiology[MESH]|Diabetes Mellitus, Type 1/*physiopathology[MESH]|Diabetic Angiopathies/*etiology[MESH]|Eicosanoids/biosynthesis[MESH]|Humans[MESH]|Inflammation/*complications[MESH]|Macrophages/metabolism[MESH]|Mice[MESH]|Monocytes/metabolism[MESH]|Myeloid Cells/metabolism[MESH] |